2029, Biosimilars and Drug Development

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Biosimilars

Drug Development

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement

Process Improvement Biosimilars Drug Development

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Documentation

Documentation Drug Development

Pharmacist Digest

Single-use technology propelling upstream bioprocessing market expansion

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

Stay Connected